Department of Internal Medicine, University of New Mexico Comprehensive Cancer Center, University of New Mexico, Albuquerque, NM, 87131, USA.
Department of Pharmaceutical Sciences, College of Pharmacy, University of New Mexico, Albuquerque, NM, 87131, USA.
DNA Repair (Amst). 2021 Jul;103:103126. doi: 10.1016/j.dnarep.2021.103126. Epub 2021 Apr 20.
Elongation of RNA polymerase II (Pol II) is affected by many factors including DNA damage. Bulky damage, such as lesions caused by ultraviolet (UV) radiation, arrests Pol II and inhibits gene transcription, and may lead to genome instability and cell death. Cells activate transcription-coupled nucleotide excision repair (TC-NER) to remove Pol II-impeding damage and allow transcription resumption. TC-NER initiation in humans is mediated by Cockayne syndrome group B (CSB) protein, which binds to the stalled Pol II and promotes assembly of the repair machinery. Given the complex nature of the TC-NER pathway and its unique function at the interface between transcription and repair, new approaches are required to gain in-depth understanding of the mechanism. Advances in genomic approaches provide an important opportunity to investigate how TC-NER is initiated upon damage-induced Pol II stalling and what factors are involved in this process. In this Review, we discuss new mechanisms of TC-NER revealed by genome-wide DNA damage mapping and new TC-NER factors identified by high-throughput screening. As TC-NER conducts strand-specific repair of mutagenic damage, we also discuss how this repair pathway causes mutational strand asymmetry in the cancer genome.
RNA 聚合酶 II(Pol II)的延伸受到许多因素的影响,包括 DNA 损伤。大体积损伤,如紫外线(UV)辐射引起的损伤,会使 Pol II 停滞并抑制基因转录,并可能导致基因组不稳定和细胞死亡。细胞激活转录偶联核苷酸切除修复(TC-NER)以去除阻碍 Pol II 的损伤,允许转录重新开始。人类 TC-NER 的启动由 Cockayne 综合征组 B(CSB)蛋白介导,该蛋白与停滞的 Pol II 结合并促进修复机制的组装。鉴于 TC-NER 途径的复杂性质及其在转录和修复之间的接口的独特功能,需要新的方法来深入了解其机制。基因组方法的进步为研究损伤诱导的 Pol II 停滞时 TC-NER 是如何启动的以及该过程涉及哪些因素提供了重要机会。在这篇综述中,我们讨论了全基因组 DNA 损伤图谱揭示的 TC-NER 的新机制以及高通量筛选鉴定的新 TC-NER 因子。由于 TC-NER 对诱变损伤进行链特异性修复,我们还讨论了该修复途径如何导致癌症基因组中突变链不对称性。